By now, everyone has seen the MIT figure: Despite $30-40 billion in enterprise investment into GenAI so far, “95% of organizations are seeing zero return.” Boards want to see results; CFOs are asking hard questions. But the promised productivity gains have remained largely theoretical so far. The reasons are twofold: the sequencing problem and the...